Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) of the Company's issued and ...
Injectable weight loss drugs such as semaglutide and tirzepatide have attracted huge attention, but new real-world data suggest they deliver far less weight loss than surgery outside clinical trials.
Unele rezultate au fost ascunse, deoarece pot fi inaccesibile pentru dvs.
Afișați rezultatele inaccesibile
Părere